Merck (MRK), Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19
Go back to Merck (MRK), Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19| Merck & Co. (NYSE: MRK) | Delayed: 149.91 +3.04 (2.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $146.87 | 52 Week High | $65.46 | |||
| Open | $146.79 | 52 Week Low | $47.97 | |||
| Day High | $150.49 | P/E | 101.98 | |||
| Day Low | $145.60 | EPS | $1.47 | |||
| Volume | 3,973,386 | |||||
